Emma Rathbone

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Robert E. Coleman, David Cameron, David Dodwell et al. · The Lancet Oncology · 2014 · 296 citations

Medicine, Oncology, Pharmacology +10

CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells

Siobhan Margaret Restorick, Lindsay Durant, Seema Kalra et al. · Brain Behavior and Immunity · 2017 · 77 citations · Full text

Life Sciences, Immunology, Pathology +17

Osteonecrosis of the Jaw and Oral Health–Related Quality of Life After Adjuvant Zoledronic Acid: An Adjuvant Zoledronic Acid to Reduce Recurrence Trial Subprotocol (BIG01/04)

Emma Rathbone, Janet E. Brown, Helen Marshall et al. · Journal of Clinical Oncology · 2013 · 56 citations · Full text

Pharmacy, Oncology, Breast Oncology +12

Cerebrospinal fluid immunoglobulin light chain ratios predict disease progression in multiple sclerosis

Emma Rathbone, Lindsay Durant, James L. Kinsella et al. · Journal of Neurology Neurosurgery & Psychiatry · 2018 · 45 citations · Full text

Life Sciences, Immunology, Neurology +17

Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial

Janet E. Brown, Emma Rathbone, Samantha Hinsley et al. · JNCI Journal of the National Cancer Institute · 2017 · 43 citations · Full text

Medicine, Biostatistics, Oncology +16